KR102359799B1 - 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법 - Google Patents

다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법 Download PDF

Info

Publication number
KR102359799B1
KR102359799B1 KR1020207012588A KR20207012588A KR102359799B1 KR 102359799 B1 KR102359799 B1 KR 102359799B1 KR 1020207012588 A KR1020207012588 A KR 1020207012588A KR 20207012588 A KR20207012588 A KR 20207012588A KR 102359799 B1 KR102359799 B1 KR 102359799B1
Authority
KR
South Korea
Prior art keywords
patient
delete delete
pharmaceutical composition
care
standard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207012588A
Other languages
English (en)
Korean (ko)
Other versions
KR20210027229A (ko
Inventor
안나 마리아 랑킬드
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Priority to KR1020217014553A priority Critical patent/KR20220044234A/ko
Publication of KR20210027229A publication Critical patent/KR20210027229A/ko
Application granted granted Critical
Publication of KR102359799B1 publication Critical patent/KR102359799B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
KR1020207012588A 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법 Active KR102359799B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217014553A KR20220044234A (ko) 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962893849P 2019-08-30 2019-08-30
US62/893,849 2019-08-30
US201962930673P 2019-11-05 2019-11-05
US62/930,673 2019-11-05
US201962946625P 2019-12-11 2019-12-11
US62/946,625 2019-12-11
US202062960756P 2020-01-14 2020-01-14
US62/960,756 2020-01-14
US202062969181P 2020-02-03 2020-02-03
US62/969,181 2020-02-03
US202062985407P 2020-03-05 2020-03-05
US62/985,407 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217014553A Division KR20220044234A (ko) 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20210027229A KR20210027229A (ko) 2021-03-10
KR102359799B1 true KR102359799B1 (ko) 2022-02-09

Family

ID=69784449

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207012588A Active KR102359799B1 (ko) 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법
KR1020217014553A Ceased KR20220044234A (ko) 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법
KR1020247038499A Pending KR20240166611A (ko) 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217014553A Ceased KR20220044234A (ko) 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법
KR1020247038499A Pending KR20240166611A (ko) 2019-08-30 2020-03-09 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법

Country Status (18)

Country Link
US (3) US10973836B2 (https=)
EP (1) EP4021507A1 (https=)
JP (4) JP7756487B2 (https=)
KR (3) KR102359799B1 (https=)
CN (1) CN112752582A (https=)
AU (4) AU2020202887B2 (https=)
BR (1) BR112020008705A2 (https=)
CA (1) CA3079175A1 (https=)
CL (1) CL2020001335A1 (https=)
CR (1) CR20200224A (https=)
IL (1) IL274020A (https=)
JO (1) JOP20200098A1 (https=)
MX (2) MX2020005388A (https=)
PE (1) PE20211267A1 (https=)
PH (1) PH12020551141A1 (https=)
SG (1) SG11202003971RA (https=)
TW (3) TWI786398B (https=)
WO (1) WO2021037400A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
EP4138826A1 (en) * 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US20240100013A1 (en) * 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023175573A1 (en) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
US20250205317A1 (en) * 2022-03-28 2025-06-26 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
CR20250112A (es) * 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
EP4640213A1 (en) * 2022-12-20 2025-10-29 THPharm Corp. Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2007093610A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
JP2011506363A (ja) 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全の処置および／または予防用のオキサゾリジノン類
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX367404B (es) 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
JP2017528499A (ja) * 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
AU2017233889B2 (en) 2016-03-16 2022-07-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising empagliflozin and uses thereof
EP3508222A4 (en) * 2016-08-30 2020-04-29 Niigata University MEDICINES FOR REMOVING AGED CELLS
WO2018142422A1 (en) 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
TW202220672A (zh) * 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF HEART FAILURE, vol. 21, no. 5, pp. 665-675 (2019.03.21.)*

Also Published As

Publication number Publication date
US20210260083A1 (en) 2021-08-26
TW202335668A (zh) 2023-09-16
JP2023025207A (ja) 2023-02-21
JOP20200098A1 (ar) 2021-02-28
TW202108134A (zh) 2021-03-01
CL2020001335A1 (es) 2021-07-09
US20240216404A1 (en) 2024-07-04
TWI786398B (zh) 2022-12-11
IL274020A (en) 2021-03-01
BR112020008705A2 (pt) 2022-03-22
WO2021037400A1 (en) 2021-03-04
KR20210027229A (ko) 2021-03-10
AU2021215150A1 (en) 2021-09-02
CN112752582A (zh) 2021-05-04
PE20211267A1 (es) 2021-07-19
CA3079175A1 (en) 2021-02-28
SG11202003971RA (en) 2021-04-29
KR20220044234A (ko) 2022-04-07
TWI859649B (zh) 2024-10-21
AU2023210548A1 (en) 2023-08-17
US20210060043A1 (en) 2021-03-04
AU2020202887A1 (en) 2021-03-18
US11903955B2 (en) 2024-02-20
AU2021215150B2 (en) 2023-05-04
MX2020005388A (es) 2022-10-25
AU2025204486A1 (en) 2025-07-03
JP7494277B2 (ja) 2024-06-03
JP2025108488A (ja) 2025-07-23
AU2023210548B2 (en) 2025-04-17
CR20200224A (es) 2021-05-26
AU2020202887B2 (en) 2021-05-20
JP2022530575A (ja) 2022-06-30
PH12020551141A1 (en) 2021-05-31
US10973836B2 (en) 2021-04-13
EP4021507A1 (en) 2022-07-06
JP7756487B2 (ja) 2025-10-20
TW202504616A (zh) 2025-02-01
MX2022008018A (es) 2022-07-27
KR20240166611A (ko) 2024-11-26
JP2024119842A (ja) 2024-09-03

Similar Documents

Publication Publication Date Title
KR102359799B1 (ko) 다파글리플로진으로 박출률이 감소된 심부전을 치료하는 방법
Anker et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
Mullens et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Seferović et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure
JP2023001136A (ja) エンパグリフロジンを含む医薬組成物及びその使用
AU2017225841A1 (en) Liraglutide in cardiovascular conditions
Zilişteanu et al. Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies
CN112336713B (zh) 达格列净在制备治疗射血分数降低的心力衰竭的药物中的用途
Murphy et al. Diabetes and CKD
HK40046452A (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
HK40046452B (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
BR122025016233A2 (pt) Usos de composições farmacêuticas que compreendem um inibidor do sglt2
HK40117723A (zh) 利用达格列净治疗射血分数降低的心力衰竭的方法
HK40051086A (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
EA042257B1 (ru) Способы лечения сердечной недостаточности со сниженной фракцией выброса с помощью дапаглифлозина
Attia et al. Effect of Dapagliflozin on the Development of Contrast-Induced Nephropathy in Diabetic Patients with ST Segment Elevation Myocardial Infarction
TW202602436A (zh) 用於治療心臟衰竭之醛固酮合成酶抑制劑
Ina et al. Effects of Luseogliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes and Established Cardiovascular Disease.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200429

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200929

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200929

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210213

Patent event code: PE09021S01D

PG1501 Laying open of application
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210513

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210708

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210213

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210708

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210513

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200929

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200908

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20211102

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210929

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210708

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210513

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200929

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200908

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250203

Start annual number: 4

End annual number: 4